Ignacio Duran, MD, PhD, of the Hospital Universitario Marqués de Valdecilla, discusses an overall survival analysis of the phase III METEOR trial of cabozantinib vs everolimus in advanced renal cell carcinoma (Abstract 550).
Rana R. McKay, MD, of the University of California, San Diego, discusses phase II study findings on atezolizumab and bevacizumab in non–clear cell renal cell carcinoma and cl...
Laurence Albiges, MD, PhD, of Gustave Roussy, discusses findings on the safety and efficacy of nivolumab used in a “real world” prospective study on metastatic renal cell car...
Thomas Powles, MD, PhD, of Queen Mary University of London, discusses phase III study findings on ramucirumab plus docetaxel vs placebo plus docetaxel in patients with advanc...
Brian C. Baumann, MD, of Washington University School of Medicine, discusses phase III study findings on adjuvant sequential chemotherapy plus radiotherapy vs adjuvant radiot...
